Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ... The firm has built a strong brand image in the market with the help ...

Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes ... growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk has more than ...

In early August, the king of Bhutan, Jigme Khesar Namgyel Wangchuck, traveled from the mountains of his landlocked Asian country to the headquarters ... EIFO and the Novo Nordisk Foundation ...

A look at news events in June 2024. 1 - Israel's government says its conditions for ending the war with Hamas have not ...

Despite a lacklustre performance from his party, instead of the landslide he expected, Modi tells a crowd at party headquarters ... Drug manufacturer Novo Nordisk says Insulin icodec is the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...